About Catalent (NYSE:CTLT)
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics. Its principal softgel technologies include traditional softgel capsules, as well as Vegicaps and OptiShell capsules. The Drug Delivery Solutions segment formulates, develops, and manufactures prescription, and consumer and animal health products using OptiMelt, OptiPact, OptiForm, and Zydis, as well as other proprietary and conventional drug delivery technologies, such as prefilled syringes; manufactures blow-fill seal unit dose consisting of ADVASEPT technology; develops biologic cell line, such as GPEx and SMARTag technologies; provides biologics; and offers analytical and bioanalytical development, and testing services. This segment also provides analytical chemical, and cell-based testing and scientific; stability testing; respiratory products formulation and manufacturing; micronization and particle engineering; regulatory consulting; and bioanalytical testing services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Industry, Sector and Symbol
Trailing P/E Ratio70.5450972824085
Forward P/E Ratio25.75
Sales & Book Value
Annual Sales$2.08 billion
Price / Sales2.53
Cash Flow$2.46 per share
Price / Cash16.02
Book Value$5.79 per share
Price / Book6.80
Net Income$109.80 million
Return on Equity23.85%
Return on Assets5.46%
Catalent (NYSE:CTLT) Frequently Asked Questions
What is Catalent's stock symbol?
Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."
How were Catalent's earnings last quarter?
Catalent (NYSE:CTLT) announced its earnings results on Monday, February, 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.10. The business earned $606.30 million during the quarter, compared to analyst estimates of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. Catalent's revenue for the quarter was up 25.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.27 earnings per share. View Catalent's Earnings History.
When will Catalent make its next earnings announcement?
Where is Catalent's stock going? Where will Catalent's stock price be in 2018?
12 brokerages have issued 12 month price objectives for Catalent's shares. Their forecasts range from $38.00 to $50.00. On average, they anticipate Catalent's share price to reach $45.60 in the next year. View Analyst Ratings for Catalent.
Who are some of Catalent's key competitors?
Some companies that are related to Catalent include Aspen Pharmacare (APNHY), Beigene (BGNE), Alkermes (ALKS), bluebird bio (BLUE), Jazz Pharmaceuticals (JAZZ), Seattle Genetics (SGEN), SAGE Therapeutics (SAGE), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Stada Arzneimittel (STDAF), Ionis Pharmaceuticals (IONS), EXACT Sciences (EXAS), Valeant Pharmaceuticals Intl (VRX), BIO-TECHNE (TECH), Dr. Reddy's Laboratories (RDY), Galapagos (GLPG), Sarepta Therapeutics (SRPT) and United Therapeutics (UTHR).
Who are Catalent's key executives?
Catalent's management team includes the folowing people:
- Mr. John R. Chiminski, Chairman, Pres & CEO (Age 54)
- Mr. Steven L. Fasman Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 55)
- Mr. William Downie, Sr. VP of Global Marketing & Sales (Age 51)
- Mr. Barry B. Littlejohns, Pres of Biologics & Specialty Drug Delivery (Age 52)
- Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 46)
Has Catalent been receiving favorable news coverage?
News articles about CTLT stock have trended somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catalent earned a coverage optimism score of 0.00 on Accern's scale. They also assigned media coverage about the company an impact score of 44.63 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Catalent's major shareholders?
Catalent's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.54%), Schroder Investment Management Group (2.78%), Champlain Investment Partners LLC (2.28%), American Century Companies Inc. (1.98%), Earnest Partners LLC (1.87%) and Brown Advisory Inc. (1.52%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Matthew M Walsh, Sharon Johnson, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.
Which major investors are selling Catalent stock?
CTLT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Bank of Montreal Can, Renaissance Technologies LLC, Two Sigma Investments LP, Goldman Sachs Group Inc., Schroder Investment Management Group and Metropolitan Life Insurance Co. NY. Company insiders that have sold Catalent company stock in the last year include Christine Dolan, John R Chiminski, Sharon Johnson and William Downie. View Insider Buying and Selling for Catalent.
Which major investors are buying Catalent stock?
CTLT stock was acquired by a variety of institutional investors in the last quarter, including American Century Companies Inc., Redmile Group LLC, Carillon Tower Advisers Inc., Hood River Capital Management LLC, Champlain Investment Partners LLC, Guggenheim Capital LLC, Segall Bryant & Hamill LLC and Fuller & Thaler Asset Management Inc.. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.
How do I buy shares of Catalent?
Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalent's stock price today?
One share of CTLT stock can currently be purchased for approximately $39.40.
How big of a company is Catalent?
Catalent has a market capitalization of $5.54 billion and generates $2.08 billion in revenue each year. The company earns $109.80 million in net income (profit) each year or $0.57 on an earnings per share basis. Catalent employs 10,800 workers across the globe.
How can I contact Catalent?
Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]
MarketBeat Community Rating for Catalent (CTLT)MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Catalent (NYSE:CTLT) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.69||2.67||2.78||2.73|
|Ratings Breakdown: ||0 Sell Rating(s)|
4 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$45.60||$45.33||$44.00||$38.60|
|Price Target Upside: ||15.74% upside||6.24% upside||11.28% upside||1.51% downside|
Catalent (NYSE:CTLT) Consensus Price Target History
Catalent (NYSE:CTLT) Analyst Ratings History
(Data available from 3/23/2016 forward)
Catalent (NYSE:CTLT) Earnings History and Estimates Chart
Catalent (NYSE CTLT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/5/2018||Q2 2018||$0.31||$0.41||$565.05 million||$606.30 million||View||N/A|
|11/6/2017||Q1 2018||$0.20||$0.21||$490.75 million||$543.90 million||View||N/A|
|8/28/2017||Q4 2017||$0.57||$0.65||$547.48 million||$616.90 million||View||N/A|
|5/4/2017||Q3 2017||$0.36||$0.38||$470.95 million||$532.60 million||View||Listen|
|2/6/2017||Q217||$0.27||$0.27||$474.07 million||$483.70 million||View||Listen|
|11/7/2016||Q117||$0.13||$0.16||$430.26 million||$442.20 million||View||Listen|
|8/29/2016||Q416||$0.53||$0.52||$498.06 million||$532.20 million||View||Listen|
|5/4/2016||Q316||$0.31||$0.20||$425.92 million||$438.00 million||View||N/A|
|2/9/2016||Q216||$0.34||$0.36||$441.99 million||$454.90 million||View||N/A|
|11/3/2015||Q116||$0.21||$0.14||$407.80 million||$423.00 million||View||N/A|
|9/2/2015||Q415||$0.58||$0.60||$496.91 million||$510.10 million||View||N/A|
|5/5/2015||Q3 2015||$0.43||$0.46||$453.25 million||$446.60 million||View||N/A|
|2/11/2015||Q215||$0.33||$0.44||$451.40 million||$455.80 million||View||N/A|
|11/13/2014||Q314||$0.20||$0.13||$411.20 million||$418.30 million||View||N/A|
|9/4/2014||Q4 2014||$1.03||$519.60 million||View||N/A|
Catalent (NYSE:CTLT) Earnings Estimates
2018 EPS Consensus Estimate: $1.20
2019 EPS Consensus Estimate: $1.80
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Catalent (NYSE:CTLT)
No dividend announcements for this company have been tracked by MarketBeat.com
Catalent (NYSE CTLT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.70%
Institutional Ownership Percentage: 99.89%
Catalent (NYSE CTLT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/8/2018||William Downie||SVP||Sell||9,082||$41.80||$379,627.60||46,986|| |
|12/12/2017||John R Chiminski||Insider||Sell||181,458||$39.62||$7,189,365.96|| |
|11/21/2017||Uwe Roehrhoff||Director||Buy||7,500||$39.22||$294,150.00|| |
|8/29/2017||Christine Dolan||SVP||Sell||1,594||$38.75||$61,767.50|| |
|8/1/2017||Christine Dolan||SVP||Sell||745||$34.85||$25,963.25|| |
|4/25/2017||Sharon Johnson||Insider||Sell||9,160||$29.00||$265,640.00|| |
|3/20/2017||John R. Chiminski||Insider||Sell||73,819||$28.62||$2,112,699.78|| |
|2/15/2017||Donald E. Morel, Jr.||Director||Buy||10,000||$29.27||$292,700.00|| |
|9/9/2016||Blackstone Management Associat||Major Shareholder||Sell||17,100,705||$23.58||$403,234,623.90|| |
|6/9/2016||Blackstone Management Associat||Major Shareholder||Sell||8,785,539||$24.51||$215,333,560.89|| |
|5/27/2016||Matthew M Walsh||Insider||Sell||21,197||$28.85||$611,533.45||105,688|| |
|8/19/2015||John R Chiminski||Insider||Sell||38,505||$33.81||$1,301,854.05|| |
|8/17/2015||John R Chiminski||Insider||Sell||35,550||$33.80||$1,201,590.00|| |
|7/20/2015||John R Chiminski||Insider||Sell||33,081||$29.40||$972,581.40|| |
|7/6/2015||John R Chiminski||Insider||Sell||33,828||$29.34||$992,513.52|| |
|6/11/2015||Blackstone Management Associat||Major Shareholder||Sell||1,844,963||$28.13||$51,898,809.19|| |
|6/8/2015||Blackstone Management Associat||Major Shareholder||Sell||12,299,753||$28.13||$345,992,051.89|| |
|4/1/2015||Scott Houlton||Insider||Sell||16,253||$30.61||$497,504.33|| |
|3/27/2015||Stephen Leonard||Insider||Sell||31,005||$30.13||$934,180.65|| |
|2/17/2015||Scott Houlton||Insider||Sell||14,538||$27.50||$399,795.00|| |
|2/13/2015||Scott Houlton||Insider||Sell||1,400||$28.28||$39,592.00|| |
Catalent (NYSE CTLT) News Headlines
Catalent (NYSE:CTLT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Catalent (NYSE:CTLT) Income Statement, Balance Sheet and Cash Flow Statement
Catalent (NYSE CTLT) Stock Chart for Friday, March, 23, 2018